Skip to main content
Thieme - PMC COVID-19 Collection logoLink to Thieme - PMC COVID-19 Collection
. 2020 May 15;16(6):716. doi: 10.1055/s-0040-1706950

Hydroxychloroquine – An Antimalarial to Fight COVID-19?

Dirk Trauner, Alexander J E Novak
PMCID: PMC7339103

graphic file with name i_t040_s1_10-1055_s-0040-1706950.gif

Significance

Hydroxychloroquine (HCQ) and chloroquine (CQ) have long been used as treatments for malaria and autoimmune diseases. Surrey and Hammer detailed the synthesis of HCQ, a potent antimalarial in 1950. In an effort to identify available drugs to fight SARS-CoV-2 it has been reported that CQ and HCQ in combination with azithromycin might have the potential to combat COVID-19.

Comment

HCQ is synthesized by reacting a diamine with 4,7-dichloroquinoline in an S N Ar reaction. The diamine is synthesized by condensing 5-chloro-2-pentanone with N -ethylethanolamine, followed by reductive amination with ammonia. HCQ showed good antimalarial activity and recently has been found to inhibit SARS-CoV-2 infection in vitro ( Cell Discovery 2020 , 6 , 16).

References

  • Surrey A R, Hammer H F.Sterling-Winthrop Research Institute, Rensselaer, USA The Preparation of 7-Chloro-4-(4-( N -ethyl- N -β-hydroxyethylamino)-1-methylbutylamino)-quinoline and Related Compounds J. Am. Chem. Soc. 1950721814–1815. [Google Scholar]

Articles from Synfacts are provided here courtesy of Thieme Medical Publishers

RESOURCES